{
    "Clinical Trial ID": "NCT00371345",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Her2/Neu-amplified Tumor, 70 mg Twice Daily (BID) Dasatinib",
        "  Participants with a Human epidermal growth factor (Her2/neu)-amplified tumor type (defined as 3+ by immunohistochemistry [IHC] or positive by fluorescent or chromogenic in situ hybridization [FISH or CISH] regardless of estrogen receptor [ER]/progesterone receptor [PgR] status) received orally 70 mg of dasatinib twice daily (BID) for a total daily dose (TDD) of 140 mg.",
        "INTERVENTION 2: ",
        "  Her2/Neu-amplified Tumor, 100 mg BID",
        "  Participants with a Human epidermal growth factor (Her2/neu)-amplified tumor type (defined as 3+ by immunohistochemistry [IHC] or positive by fluorescent or chromogenic in situ hybridization [FISH or CISH] regardless of estrogen receptor [ER]/progesterone receptor [PgR] status) received orally 100 mg of dasatinib twice daily (BID) for a total daily dose (TDD) of 200 mg."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  females, 18 or older",
        "  recurrent, locally advanced, or metastatic breast cancer with expression of ER/PR receptor and/or overexpression of Her2/neu",
        "  paraffin-embedded tissue block must be available",
        "  measurable disease",
        "  prior chemotherapy with an anthracycline and/or a taxane (neoadjuvant, adjuvant, or metastatic setting)",
        "  0, 1 or 2 chemotherapies in the metastatic setting",
        "  adequate organ function",
        "Exclusion Criteria:",
        "  Metastatic disease confined to bone only",
        "  Symptomatic central nervous system (CNS) metastasis",
        "  Concurrent medical condition which may increase the risk of toxicity",
        "  Unable to take oral medication"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Number of Participants With Objective Response",
        "  Tumor response was assessed according RECIST criteria: PR=at least 30% reduction in the sum of the LD of all target lesions in reference to the baseline sum LD, CR=Disappearance of all non-target lesions. Objective tumor response was defined as a PR or CR.",
        "  Time frame: From day of first treatment through Week 25 or at time of discontinuation from study treatment.",
        "Results 1: ",
        "  Arm/Group Title: Her2/Neu-amplified Tumor, 70 mg Twice Daily (BID) Dasatinib",
        "  Arm/Group Description: Participants with a Human epidermal growth factor (Her2/neu)-amplified tumor type (defined as 3+ by immunohistochemistry [IHC] or positive by fluorescent or chromogenic in situ hybridization [FISH or CISH] regardless of estrogen receptor [ER]/progesterone receptor [PgR] status) received orally 70 mg of dasatinib twice daily (BID) for a total daily dose (TDD) of 140 mg.",
        "  Overall Number of Participants Analyzed: 15",
        "  Measure Type: Number",
        "  Unit of Measure: participants  0",
        "Results 2: ",
        "  Arm/Group Title: Her2/Neu-amplified Tumor, 100 mg BID",
        "  Arm/Group Description: Participants with a Human epidermal growth factor (Her2/neu)-amplified tumor type (defined as 3+ by immunohistochemistry [IHC] or positive by fluorescent or chromogenic in situ hybridization [FISH or CISH] regardless of estrogen receptor [ER]/progesterone receptor [PgR] status) received orally 100 mg of dasatinib twice daily (BID) for a total daily dose (TDD) of 200 mg.",
        "  Overall Number of Participants Analyzed: 9",
        "  Measure Type: Number",
        "  Unit of Measure: participants  1"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 20/70 (28.57%)",
        "  NAUSEA 2/70 (2.86%)",
        "  VOMITING 1/70 (1.43%)",
        "  DIARRHOEA 2/70 (2.86%)",
        "  ABDOMINAL PAIN 1/70 (1.43%)",
        "  ABDOMINAL PAIN LOWER 1/70 (1.43%)",
        "  FATIGUE 2/70 (2.86%)",
        "  PYREXIA 1/70 (1.43%)",
        "  OEDEMA PERIPHERAL 1/70 (1.43%)",
        "  GENERAL PHYSICAL HEALTH DETERIORATION 3/70 (4.29%)",
        "  PNEUMONIA 1/70 (1.43%)",
        "  SINUSITIS 1/70 (1.43%)",
        "  LOBAR PNEUMONIA 1/70 (1.43%)",
        "Adverse Events 2:",
        "   "
    ]
}